Nadia Cocero1, Fabrizio Pucci1, Maria Messina2, Berardino Pollio2, Marco Mozzati3, Laura Bergamasco1. 1. Oral Surgery Unit, Dental School, Joint Hospital-University Institution "Città della Salute e della Scienza", Turin, Italy. 2. Centre for Inherited Bleeding and Thrombotic Disorders, Transfusion Unit, Joint Hospital-University Institution "Città della Salute e della Scienza", Turin, Italy. 3. SIOM Oral Surgery and Implantology Centre, Turin, Italy.
Abstract
BACKGROUND: Dental extractions in haemophiliacs may cause secondary bleeding, requiring repeated surgical and haematological interventions. As a local haemostatic, fibrin glue has recognised efficacy but, as a plasma-derived product, it carries the risk of viral infections. We, therefore, compared fibrin glue with an autologous haemostatic, plasma rich in growth factors (PRGF), in a controlled trial. MATERIAL AND METHODS: One hundred and twenty patients with different blood disorders were randomised into two cohorts to undergo dental extraction procedures without hospitalisation. Prior to the extractions, patients underwent systemic haematological treatment. Complications were defined as secondary bleeding after the 7-day follow-up period or protracting after the repair procedure. RESULTS: There were 106 extractions (7 retained 3(rd) molars) in the group managed with fibrin glue: secondary bleeding affected 3/60 patients (5%) on the third day after extraction and necessitated additional surgery and systemic treatment (in one case the procedure had to be repeated on the 7(th) day). In the PRGF arm there were 98 extractions (23 retained 3(rd) molars): secondary bleeding affected two patients (3.3%) on the first day after extraction and was arrested with surgery without systemic treatment. Four out of the five secondary bleeds occurred in patients with haemophilia A. Concomitant diabetes or liver disease significantly increased the bleeding risk. DISCUSSION: The bleeding rates in the study and control arm prove that PRGF works as well as fibrin glue as a local haemostatic. Further assets are that PRGF has autologous origin, does not require additional systemic treatment in post-extraction repair surgery, is associated with an earlier onset of neo-angiogenesis and, overall, can reduce patients' distress and costs to the health system.
RCT Entities:
BACKGROUND: Dental extractions in haemophiliacs may cause secondary bleeding, requiring repeated surgical and haematological interventions. As a local haemostatic, fibrin glue has recognised efficacy but, as a plasma-derived product, it carries the risk of viral infections. We, therefore, compared fibrin glue with an autologous haemostatic, plasma rich in growth factors (PRGF), in a controlled trial. MATERIAL AND METHODS: One hundred and twenty patients with different blood disorders were randomised into two cohorts to undergo dental extraction procedures without hospitalisation. Prior to the extractions, patients underwent systemic haematological treatment. Complications were defined as secondary bleeding after the 7-day follow-up period or protracting after the repair procedure. RESULTS: There were 106 extractions (7 retained 3(rd) molars) in the group managed with fibrin glue: secondary bleeding affected 3/60 patients (5%) on the third day after extraction and necessitated additional surgery and systemic treatment (in one case the procedure had to be repeated on the 7(th) day). In the PRGF arm there were 98 extractions (23 retained 3(rd) molars): secondary bleeding affected two patients (3.3%) on the first day after extraction and was arrested with surgery without systemic treatment. Four out of the five secondary bleeds occurred in patients with haemophilia A. Concomitant diabetes or liver disease significantly increased the bleeding risk. DISCUSSION: The bleeding rates in the study and control arm prove that PRGF works as well as fibrin glue as a local haemostatic. Further assets are that PRGF has autologous origin, does not require additional systemic treatment in post-extraction repair surgery, is associated with an earlier onset of neo-angiogenesis and, overall, can reduce patients' distress and costs to the health system.
Authors: M Franchini; G Rossetti; A Tagliaferri; C Pattacini; D Pozzoli; C Lorenz; L Del Dot; G Ugolotti; C Dell'aringa; G Gandini Journal: Haemophilia Date: 2005-09 Impact factor: 4.287
Authors: Eduardo Anitua; José J Aguirre; Jaime Algorta; Eduardo Ayerdi; Ana I Cabezas; Gorka Orive; Isabel Andia Journal: J Biomed Mater Res B Appl Biomater Date: 2008-02 Impact factor: 3.368